HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

golimumab

Golimumab plus MTX effectively reduces the signs and symptoms of RA and is generally well tolerated in patients with an inadequate response to MTX.
Also Known As:
CNTO 148; CNTO-148; Simponi
Networked: 771 relevant articles (168 outcomes, 266 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Hsia, Elizabeth C: 43 articles (12/2022 - 04/2008)
2. Xu, Stephen: 27 articles (12/2022 - 06/2010)
3. Xu, Zhenhua: 25 articles (01/2022 - 03/2007)
4. Rahman, Mahboob U: 23 articles (01/2014 - 03/2007)
5. Kavanaugh, Arthur: 22 articles (01/2022 - 04/2009)
6. van der Heijde, Désirée: 22 articles (01/2022 - 09/2010)
7. Deodhar, Atul: 18 articles (12/2022 - 09/2010)
8. Lo, Kim Hung: 17 articles (12/2022 - 04/2009)
9. Kim, Lilianne: 17 articles (09/2021 - 04/2010)
10. Hsu, Benjamin: 17 articles (12/2016 - 11/2008)

Related Diseases

1. Ulcerative Colitis
2. Rheumatoid Arthritis
3. Psoriatic Arthritis
4. Ankylosing Spondylitis
5. Uveitis

Related Drugs and Biologics

1. Infliximab (Remicade)
2. Adalimumab (Humira)
3. Methotrexate (Mexate)
4. Etanercept (Enbrel)
5. Certolizumab Pegol
6. Tumor Necrosis Factor Inhibitors
7. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
8. Ustekinumab (CNTO 1275)
9. Monoclonal Antibodies
10. vedolizumab

Related Therapies and Procedures

1. Therapeutics
2. Aftercare (After-Treatment)
3. Biological Therapy
4. Activities of Daily Living (ADL)
5. Off-Label Use